Chidiac, C <br/><br/>
Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.).  [electronic resource] 

 -  Medecine et maladies infectieuses  Sep 2015 
 - 348-73 p.  digital 
<br/><br/> Publication Type: Journal Article; Practice Guideline 
<br/><br/><label>ISSN: </label>1769-6690 
<br/><br/><label>Standard No.: </label>10.1016/j.medmal.2015.07.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anti-Bacterial Agents--adverse effects<br/>Antibiotic Prophylaxis<br/>Bacterial Infections--drug therapy<br/>Bacterial Proteins--antagonists & inhibitors<br/>Biotransformation<br/>Chemical and Drug Induced Liver Injury--etiology<br/>Child<br/>Contraindications<br/>DNA Gyrase--genetics<br/>DNA Topoisomerase IV--genetics<br/>Drug Resistance, Multiple, Bacterial--genetics<br/>Female<br/>Fluoroquinolones--adverse effects<br/>France<br/>Gastrointestinal Diseases--chemically induced<br/>Humans<br/>Long QT Syndrome--chemically induced<br/>Male<br/>Mutation<br/>Photosensitivity Disorders--chemically induced<br/>Pregnancy<br/>Pregnancy Complications, Infectious--drug therapy<br/>Tendinopathy--chemically induced<br/>Tissue Distribution<br/>Topoisomerase II Inhibitors--adverse effects<br/>Young Adult